BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ampligen rintatolimod: Phase I/II started

Hemispherx said investigators began an open-label, U.S. Phase I/II trial to evaluate 4, 20, 79 and 495 µg intradermal Ampligen plus the university's vaccine consisting of synthetic peptide...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >